

32692

Customer Number



Patent

Case No.: 58767US003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: MILLER, RICHARD L.
Application No.: 10/821330 Group Art Unit: 1644
Filed: April 9, 2004 Examiner: Unknown
Title: METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR § 1.8(a)]

I hereby certify that this correspondence is being:

- ☒ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) 872-9306.

November 22, 2004

Date

Virginia Bergstrom

Signed by: Virginia Bergstrom

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

Copies of any cited foreign patents, foreign publications, non-patent literature documents; and any pending U.S. applications filed before June 30, 2003, are enclosed. Copies of any pending U.S. applications filed after June 30, 2003 that can be accessed on the USPTO's IFW system are not enclosed as per USPTO Waiver dated September 21, 2004. Copies of any U.S. patents and published U.S. patent applications are not enclosed.

It is believed that no fee is due; however, in the event a fee is required, please charge the fee to Deposit Account No. 13-3723.

Respectfully submitted,

Nov. 22, 2004

Date

By:

Ted K. Ringsred
Ted K. Ringsred, Reg. No.: 35,658
Telephone No.: (651) 736-5839

Office of Intellectual Property Counsel
3M Innovative Properties Company
Facsimile No.: 651-736-3833

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 1 of 8

Application Number

10/821330

Filing Date

April 9, 2004

First Named Inventor

Miller, Richard L.

Art Unit


1644

Examiner Name

Unknown

Attorney Case Number

58767US003



U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A1	US- 3,314,941	04-18-1967	Littell et al.	
	A2	US- 4,528,325	07-09-1985	Ofstead	
	A3	US- 4,618,649	10-21-1986	Ofstead	
	A4	US- 4,658,325	04-14-1987	Splitt	
	A5	US- 4,689,338	08-25-1987	John F. Gerster	
	A6	US- 4,698,348	10-06-1987	John F. Gerster	
	A7	US- 4,722,906	02-02-1988	Guire	
	A8	US- 4,929,624	05-29-1990	Gerster et al.	
	A9	US- 4,973,493	11-27-1990	Guire	
	A10	US- 4,979,959	12-25-1990	Guire	
	A11	US- 4,988,815	01-29-1991	Andre et al.	
	A12	US- 5,002,582	03-26-1991	Guire et al.	
	A13	US- 5,037,986	08-06-1991	John F. Gerster	
	A14	US- 5,175,296	12-29-1992	Gerster	
	A15	US- 5,217,492	06-08-1993	Guire et al.	
	A16	US- 5,238,944	08-24-1993	Wick et al.	
	A17	US- 5,258,041	11-02-1993	Guire et al.	
	A18	US- 5,263,992	11-23-1993	Guire	
	A19	US- 5,266,575	11-30-1993	John F. Gerster	
	A20	US- 5,268,376	12-07-1993	John F. Gerster	
	A21	US- 5,346,905	09-13-1994	John F. Gerster	
	A22	US- 5,352,784	10-04-1994	Nikolaides et al.	
	A23	US- 5,367,076	11-22-1994	Gerster	
	A24	US- 5,376,501	12-27-1994	Marien et al.	
	A25	US- 5,389,640	02-14-1995	Gerster et al.	
	A26	US- 5,395,937	03-07-1995	Nikolaides et al.	
	A27	US- 5,446,153	08-29-1995	Lindstrom et al.	
	A28	US- 5,482,936	01-09-1996	Kyle J. Lindstrom	

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 2 of 8

Application Number

10/821330

Filing Date

April 9, 2004

First Named Inventor

Miller, Richard L.

Art Unit

1644

Examiner Name

Unknown

Attorney Case Number

58767US003

U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A29	US- 5,494,916	02-27-1996	Lindstrom et al.	
	A30	US- 5,525,612	06-11-1996	Gerster	
	A31	US- 5,605,899	02-25-1997	Gerster et al.	
	A32	US- 5,693,811	12-02-1997	Lindstrom	
	A33	US- 5,741,908	04-21-1998	Gerster et al.	
	A34	US- 5,756,747	05-26-1998	Gerster et al.	
	A35	US- 5,939,090	08-17-1999	Beaurline et al.	
	A36	US- 6,028,076	02-22-2000	Hirota et al.	
	A37	US- 6,039,969	03-21-2000	Tomai et al.	
	A38	US- 6,069,149	05-30-2000	Nanba et al.	
	A39	US- 6,083,505	07-04-2000	Miller et al.	
	A40	US- 6,110,929	08-29-2000	Gerster et al.	
	A41	US- 6,113,918	09-05-2000	Johnson et al.	
	A42	US- 6,126,919	10-03-2000	Stefely et al.	
	A43	US- 6,194,388	02-27-2001	Krieg et al.	
	A44	US- 6,194,425	02-27-2001	Gerster et al.	
	A45	US- 6,200,592	03-13-2001	Tomai et al.	
	A46	US- 6,207,646	03-27-2001	Krieg et al.	
	A47	US- 6,239,116	05-29-2001	Krieg et al.	
	A48	US- 6,245,776	06-12-2001	Skwierzynski et al.	
	A49	US- 6,303,347	10-16-2001	Johnson et al.	
	A50	US- 6,323,200	11-27-2001	Gerster et al.	
	A51	US- 6,329,381	12-11-2001	Kurimoto et al.	
	A52	US- 6,331,539	12-18-2001	Crooks et al.	
	A53	US- 6,339,068	01-15-2002	Krieg et al.	
	A54	US- 6,376,501	04-23-2002	Isobe et al.	
	A55	US- 6,376,669	04-23-2002	Rice et al.	
	A56	US- 6,387,938	05-14-2002	Mizuguchi et al.	

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 3 of 8

Application Number

10/821330

Filing Date

April 9, 2004

First Named Inventor

Miller, Richard L.

Art Unit

1644

Examiner Name

Unknown

Attorney Case Number

58767US003

U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A57	US- 6,406,705	06-18-2002	Davis et al.	
	A58	US- 6,440,992	08-27-2002	Gerster et al.	
	A59	US- 6,426,334	07-30-2002	Agrawal et al.	
	A60	US- 6,476,000	11-05-2002	Agrawal	
	A61	US- 6,451,810	09-17-2002	Coleman et al.	
	A62	US- 6,514,985	02-04-2003	Gerster et al.	
	A63	US- 6,518,265	02-11-2003	Kato et al.	
	A64	US- 6,518,280	02-11-2003	Gerster et al.	
	A65	US- 6,525,028	02-25-2003	Johnson et al.	
	A66	US- 6,525,064	02-25-2003	Dellaria et al.	
	A67	US- 6,541,485	04-01-2003	Crooks et al.	
	A68	US- 6,545,016	04-08-2003	Dellaria et al.	
	A69	US- 6,545,017	04-08-2003	Dellaria et al.	
	A70	US- 6,558,951	05-06-2003	Tomai et al.	
	A71	US- 6,573,273	06-03-2003	Crooks et al.	
	A72	US- 6,656,938	12-02-2003	Crooks et al.	
	A73	US- 6,649,172	11-18-2003	Johnson	
	A74	US- 6,660,735	12-09-2003	Crooks et al.	
	A75	US- 6,660,747	12-09-2003	Crooks et al.	
	A76	US- 6,664,260	12-16-2003	Charles et al.	
	A77	US- 6,664,264	12-16-2003	Dellaria et al.	
	A78	US- 6,664,265	12-16-2003	Crooks et al.	
	A79	US- 6,667,312	12-23-2003	Bonk et al.	
	A80	US- 6,670,372	12-30-2003	Charles et al.	
	A81	US- 6,677,347	01-13-2004	Crooks et al.	
	A82	US- 6,677,348	01-13-2004	Heppner et al.	
	A83	US- 6,677,349	01-13-2004	Griesgraber	
	A84	US- 6,683,088	01-27-2004	Crooks et al.	

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Page 4 of 8

Application Number

10/821330

Filing Date

April 9, 2004

First Named Inventor

Miller, Richard L.

Art Unit

1644

Examiner Name

Unknown

Attorney Case Number

58767US003

U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A85	US- 2002/0016332 A1	02-07-2002	Slade	
	A86	US- 2002/0055517 A1	05-09-2002	Smith	
	A87	US- 2002/0058674 A1	05-16-2002	Hedenstrom et al.	
	A88	US- 2002/0110840 A1	08-15-2002	Tomai et al.	
	A89	US- 2003/0130299 A1	07-10-2003	Crooks et al.	
	A90	US- 2003/0133913 A1	07-17-2003	Tomai et al.	
	A91	US- 2003/0139364 A1	07-24-2003	Krieg et al.	
	A92	US- 2003/0144283	07-31-2003	Coleman et al.	
	A93	US- 2003/0161797 A1	08-28-2003	Miller et al.	
	A94	US- 2003/0199538 A1	10-23-2003	Skwierzynski et al.	
	A95	US- 2003/0199461 A1	10-23-2003	Averett et al.	
	A96	US- 2003/0232852 A1	12-18-2003	Lindstrom et al.	
	A97	US- 2004/0010007	01-15-2004	Dellaria et al.	
	A98	US- 2004/0014779	01-22-2004	Gorden et al.	

Foreign Patent Documents

Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (If known)				
	B1	WIPO	WO 00/47719	08-17-2000			
	B2	WIPO	WO 00/75304	12-14-2000			
	B3	WIPO	WO 00/76505	2-21-2000			
	B4	WIPO	WO 00/76518	12-21-2000			
	B5	WIPO	WO 01/74343 A2	10-11-2001			
	B6	WIPO	WO 02/36592	05-10-2002			X
	B7	WIPO	WO 02/24225	03-28-2002			
	B8	WIPO	WO 02/46194	06-13-2002			
	B9	WIPO	WO 02/46749	06-13-2002			
	B10	WIPO	WO 02/085905	10-31-2002			X
	B11	WIPO	WO 02/102377	12-27-2002			

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 5 of 8	Application Number	10/821330
	Filing Date	April 9, 2004
	First Named Inventor	Miller, Richard L.
	Art Unit	1644
	Examiner Name	Unknown
	Attorney Case Number	58767US003

Foreign Patent Documents							
Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (If known)				
	B12	WIPO	WO 03/020889	03-13-2003			
	B13	WIPO	WO 03/043572	05-30-2003			
	B14	WIPO	WO 03/043573	05-03-2003			
	B15	WIPO	WO 03/043588	05-30-2003			X
	B16	WIPO	WO 03/045391	06-05-2003			
	B17	WIPO	WO 03/103584	12-18-2003			
	B18	JP	9-208584	08-12-1997			
	B19	JP	9-255926	03-26-1999			X
	B20	JP	11-222432	08-17-1999			X
	B21	JP	2000-247884 (abs)	09-12-2000			X
	B22	EP	0 394 026	10-24-1990			
	B23	EP	1 104 764	06-06-2001			
	B24	EP	1 256 582	11-13-2002			

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	Wozniak, et al, "The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate ^{1,2} . A New and Convenient Amination Method.", <u>Journal of the Royal Netherlands Chemical Society</u> , 102, pp 511-513, December 12, 1983.
	C2	Brennan, et al, "Automated Bioassay of Interferons in Micro-test Plates", <u>Biotechniques</u> , June/July, 78, 1983
	C3	Testerman, et al., "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", <u>Journal of Leukocyte Biology</u> , Volume 58, pp. 365-372, September 1995
	C4	Bachman, et al, "Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline", <u>J. Org. Chem.</u> , 15, pp 1278-1284, 1950
	C5	Jain, et al, "Chemical and Pharmacological Investigations of Some ω -Substituted Alkylamino-3-aminopyridines", <u>J. Med. Chem.</u> , 11, pp 87-92, 1968
	C6	Baranov, et al., <u>Chem. Abs.</u> 85, 94362, 1976
	C7	Berényi, et al, "Ring Transformation of Condensed Dihydro-as-triazines", <u>J. Heterocyclic Chem.</u> , 18, pp 1537-1540, 1981
	C8	Chollet, et al, "Development of a Topically Active Imiquimod Formulation", <u>Pharmaceutical Development and Technology</u> , 4(1), pp 35-43, 1999

*Examiner:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for form 1449/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 6 of 8	Application Number	10/821330
	Filing Date	April 9, 2004
	First Named Inventor	Miller, Richard L.
	Art Unit	1644
	Examiner Name	Unknown
	Attorney Case Number	58767US003

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C9	Izumi, et al., "1H-Imidazo[4,5-c]quinoline Derivatives as Novel Potent TNF- α Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2- and 4-Substituted 1H-imidazo[4,5-c]pyridines", <u>Bioorganic & Medicinal Chemistry</u> , 11, pp 2541-2550, 2003
	C10	Nam et al., "Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins", <u>Science</u> , pp. 1884-1886, September 2003
	C11	Geisse et al., "Imiquimod 5% Cream for the Treatment of Superficial Basal Cell Carcinoma: A Double-Blind, Randomized, Vehicle-Controlled Study", <u>J. Am. Acad. Dermatol.</u> , Vol. 47, No. 3, pp. 390-398, September 2002
	C12	Shumack et al., "Efficacy of Topical 5% Imiquimod Cream for the Treatment of Nodular Basal Cell Carcinoma", <u>Arch. Dermatol.</u> , vol. 138, pp. 1165-1171, September 2002
	C13	Gref et al., "'Stealth' Corona-Core Nanoparticles Surface Modified by Polyethylene Glycol (PEG): Influences of the Corona (PEG Chain Length and Surface Density) and of the Core Composition on Phagocytic Uptake and Plasma Protein Adsorption", <u>Colloids and Surfaces B: Biointerfaces</u> , 18, pp. 301-313, 2000
	C14	Bayer et al., "Application of Avidin-Biotin Technology to Affinity-Based Separations", <u>Journal of Chromatography</u> , 510, pp. 3-11, 1990
	C15	Kinoshita et al., "Soft Tissue Reaction to Collagen-Immobilized Porous Polyethylene: Subcutaneous Implantation in Rats for 20 wk", <u>Biomaterials</u> , Vol. 14, No. 3, pp.209-215, 1993
	C16	Vogel et al., "A Compendium of Vaccine Adjuvants and Excipients" 2 nd Edition, Bethesda, MD: National Institute of Allergy & Infectious Disease 1998, (www.niaid.nih.gov/hivvaccines/pdf/compendium.pdf)
	C17	Sawhney et al., "Bioerodible Hydrogels Based on Photopolymerized poly(ethylene glycol)-co-poly(α -hydroxy acid) Diacrylate Macromers", <u>Macromolecules</u> , 26, pp. 581-587, 1993
	C18	Drachman, "Clinical Experience with Drug-Eluting Stents", <u>Rev Cardiovasc Med.</u> , 3 (suppl 5): S31-S37, 2002
	C19	Heldman et al., "Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis", <u>Circulation</u> , 103, pp. 2289-2295, 2001
	C20	Lepor et al., "Effective and Efficient Strategies for Coronary Revascularization in the Drug-Eluting Stent Era", <u>Rev Cardiovasc Med.</u> , 3 (suppl 5): S38-S50, 2002
	C21	Rensing et al., "Coronary Restenosis Elimination with a Sirolimus Eluting Stent, First European Human Experience with 6-month Angiographic and Intravascular Follow-up", <u>Eur. Heart J</u> , 22, pp. 2125-2130, 2001
	C22	Rogers, "Drug-Eluting Stents: Role of Stent Design, Delivery Vehicle, and Drug Selection", <u>Rev Cardiovasc Med.</u> , 3 (suppl 5): S10-S15, 2002
	C23	Schwartz et al., "Pathophysiology of Coronary Artery Restenosis", <u>Rev Cardiovasc Med.</u> 3 (suppl 5): S4-S9, 2002

*Examiner:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for form 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 7 of 8	Application Number	10/821330
	Filing Date	April 9, 2004
	First Named Inventor	Miller, Richard L.
	Art Unit	1644
	Examiner Name	Unknown
	Attorney Case Number	58767US003

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C24	Kariko et al., "Small Interfering RNA's Mediate Sequence-Independent Gene Suppression and Induce Immune Activation by Signaling through Toll-like Receptor 3", <u>Journal of Immunology</u> , pp. 6545-6549, June 2004
	C25	Cholakos et al., "Effect of Heparin-PVA hydrogel on Platelets in a Chronic Canine Arterio-Venous Shunt", <u>Journal of Biomedical Materials Research</u> , Vol. 23, pp. 417-441, 1989
	C26	Cholakos et al., "In vitro Platelet Interactions with a Heparin-Polyvinyl Alcohol Hydrogel", <u>Journal of Biomedical Materials Research</u> , Vol. 23, pp. 399-415, 1989
	C27	Sousa et al., "Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents, One-Year Angiographic and Intravascular Ultrasound Follow-Up", 104: pp. 2007-2011, <u>Circulation</u> 2001
	C28	O'Hagan et al., "Microparticles as Vaccine Adjuvants and Delivery Systems", <u>Expert Rev. Vaccines</u> 2 (2), pp. 269-283, 2003
	C29	Thomsen, "Imiquimod and Resiquimod are Adjuvants for DNA vaccination by Particle-Mediated Delivery (PMID)" Gene and Protein Therapeutics Department, GlaxoSmithKline, Stevenage, UK, Modern Vaccines Adjuvants and Delivery Systems meeting, Dublin, Ireland, June 4-6, 2003
	C30	Furumoto et al., "Induction of Potent Antitumor Immunity by in situ Targeting of Intratumoral DCs", <u>The Journal of Clinical Investigation</u> , Vol. 113, Number 5, pp. 774-783, March 2004
	C31	Kito et al., "Differentiated Biocompatible Design of Luminal and Outer Graft Surfaces- Photocurable Extracellular Matrices, Fabrication, and Cellular Response", <u>ASAIO Journal</u> , M506-M511, 1993
	C32	Green, "Avidin, The Nature of the Biotin-Binding Site", <u>Biochem. J.</u> , 89, pp. 599-609, March 19, 1963
	C33	Wei et al., "Dissociation of Avidin-Biotin Complex in vivo", <u>Experientia</u> , Vol. 27, pp. 366-368, 1970
	C34	Green, "Advances in Protein Chemistry", Academic Press, Vol. 29, pp. 85-133, Copyright 1975
	C35	Hermanson, "Bioconjugate Techniques", Chapter 2, "The Chemistry of Reactive Groups", Academic Press, pp. 137-166, Copyright 1996
	C36	Hermanson, "Bioconjugate Techniques", Chapter 5, "Heterobifunctional Cross-Linkers", Academic Press, pp. 229-285, Copyright 1996
	C37	Clapper et al., "Covalently Immobilized ECM Proteins Improve Patency and Endothelialization of 4 MM Grafts Implanted in Dogs", <u>Trans. Soc., Biomat.</u> 16, p. 42, 1993
	C38	U.S. patent application Serial Number 60/432650, Gupta et al., "Assays Relating to Toll-Like Receptor Activity" filed December 11, 2002
	C39	U.S. patent application Serial Number 60/432651, Gupta et al., "Gene Expression Systems and Recombinant Cell Lines" filed December 11, 2002
	C40	U.S. patent application Serial Number 60/437398, Ross M. Kedl, "Immunostimulatory Compositions", filed December 20, 2002
	C41	U.S. patent application Serial Number 60/447179, Gordon et al., "Methods and Compositions Related to IRM Compounds and Toll-Like Receptor 8" filed February 13, 2003

*Examiner:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for form 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 8 of 8	Application Number	10/821330
	Filing Date	April 9, 2004
	First Named Inventor	Miller, Richard L.
	Art Unit	1644
	Examiner Name	Unknown
	Attorney Case Number	58767US003

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C42	U.S. patent application Serial Number 60/462140, Wightman et al., "Delivery of Immune Response Modifier Compounds" filed April 10, 2003
	C43	U.S. patent application Serial Number 60/515256, Liu et al., "Delivery of Immune Response Modifier Compounds Using Metal-Containing particulate Support Materials" filed October 29, 2003
	C44	U.S. patent application Serial Number 60/515604, Paul D. Wightman, "Lipid-Modified Immune Response Modifiers" filed October 30, 2003
	C45	U.S. patent application Serial Number 10/626261, Oxman et al., "Hardenable Thermally Responsive Compositions" filed July 24, 2003
	C46	U.S. patent application Serial Number 10/732,563, Gupta et al., "Assays Relating to Toll-Like Receptor Activity", filed December 10, 2003
	C47	U.S. patent application Serial Number 10/788,731, Fink et al., "Selective Modulation of TLR-Mediated Biological Activity" filed February 27, 2004
	C48	U.S. patent application Serial Number 10/777,310, Wood et al, "Methods and Compositions Related to IRM Compounds and Toll-Like Receptor 8" filed February 12, 2004

*Examiner:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	